TerminatedPhase 1NCT02630927

A Safety and Tolerability Study of AG-519 in Healthy Subjects

Studying Rare anemia

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Agios Pharmaceuticals, Inc.
Principal Investigator: Gary A Connor, RN
Agios Pharmaceuticals, Inc.
Intervention: AG-519(drug)
Enrollment: 108 enrolled
Eligibility: 18-60 years · All sexes
Timeline: 2015 – 2016

Study locations (1)

Quotient Clinical, Ruddington Fields, Nottingham, United Kingdom

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02630927 on ClinicalTrials.gov

← Back to all trials